William J. Rieflin

Mr. Rieflin became chair of Lycia’s Board of Directors in December 2020.  He is currently Executive Chairman of the Board of Directors of NGM (NASDAQ:  NGM), after having served as Chief Executive Officer of the company and a member of its Board from September 2010 to September 2018. Prior to joining NGM, he was President of XenoPort, Inc. (NASDAQ: XNPT), which was acquired by Arbor Pharmaceuticals in 2016, and Executive Vice President, Administration, Chief Financial Officer, General Counsel and Secretary for Tularik Inc. (NASDAQ: TLRK), which was acquired by Amgen Inc. in 2004. Previously, he was Vice President, Human Resources, General Counsel and Secretary for AMSCO International, Inc. (NYSE: ASZ). He was also an associate at Sidley & Austin in the corporate and securities department. In addition to Lycia and NGM, he is currently on the Board of Directors of Kallyope, Inc., Lyell Immunopharma, Inc. (NASDAQ: LYEL) and RAPT Therapeutics, Inc. (NASDAQ:  RAPT). Mr. Rieflin earned his B.S. from Cornell University, his M.B.A. from the University of Chicago Booth School of Business and his J.D. from Stanford Law School.